VANCOUVER, British Columbia—M Pharmaceutical Inc. announced recently that it had executed on a letter of intent to acquire the assets of 40J’s LLC and related companies and technologies. M Pharma will acquire 100 percent of the worldwide rights to the included products and technologies for $1.5 million in cash and roughly 80 million shares, to be issued or paid over the next two years, along with milestone payments. The deal is subject to due diligence, exchange approval and other customary closing conditions. Gary Thompson, CEO of M Pharmaceutical USA, said that “This acquisition is a very exciting advancement for M Pharma.” As part of the deal, M Pharma also plans to continue advancing development of a patented drug product for treating female sexual dysfunction, which Thompson noted is “topical, local and non-systemic, with daily and on-demand use, while being non-hormonal and not a central nervous system drug.”